

**Table SI.** Linear regression analysis of urinary 8-hydroxydeoxyguanosine/creatinine ratio (n=405).

Parameter	r-value	95% CI	P-value
Age	-0.010	-0.107-0.0882	0.846
PSA	0.019	-0.079-0.116	0.707
Prostate volume	0.097	-0.0008-0.192	0.052
PSAD	0.003	-0.098-0.104	0.952

PSA, prostate-specific antigen; PSAD prostate-specific antigen density; CI, confidence interval.

**Table SII.** Basic characteristics of the studied patients with an initial benign biopsy.

Parameter	Initially benign	Prostatitis	PIN and atypical gland	Later malignancy	P-value <sup>a</sup>
Number of patients	174	39	9	9	
Age, years					0.922
Median	66	66	67	63	
Range	43-86	50-80	50-80	55-73	
25-75% percentile	61, 72	60, 72	56, 71	61, 70	
PSA, ng/ml					0.211
Geometric mean	7.6	8.9	7.6	10.9	
95% CI	6.9-8.3	7.2-11.1	4.3-13.4	7.0-16.8	
Prostate volume, ml					0.506
Mean ± SD	55.3±27.0	55.8±26.4	56.5±31.1	41.5±24.5	
PSAD, ng/ml/ml <sup>b</sup>					0.027
Geometric mean	0.15	0.18	0.15	0.31	
95% CI	0.14-0.17	0.14-0.22	0.09-0.25	0.19-0.50	
8-OHdG/creatinine, x10 <sup>-6</sup>					0.165
Geometric mean	4.3	4.7	3.6	1.7	
95% CI	3.8-4.8	3.9-5.7	2.0-6.7	0.9-3.2	
8-OHdG/creatinine/prostate volume, x10 <sup>-6</sup> /ml					0.625
Median	0.09	0.09	0.07	0.05	
95% CI	0.08-0.10	0.07-0.11	0.03-0.15	0.02-0.10	

<sup>a</sup>One-way ANOVA; <sup>b</sup>initially benign vs. later malignancy, P=0.0183 using post-hoc analysis with Tukey's multiple comparisons test. 8-OHdG, 8-hydroxydeoxyguanosine; PSA, prostate-specific antigen; CI, confidence interval.

**Table III.** Pathological characteristics of patients with PCa according to the time of diagnosis.

Parameter	Total	Initial PCa	Later PCa	P-value
Number of patients	187	178	9	
Radical prostatectomy	50	45	5	
Gleason grade				
3+3	23	22	1	0.508 <sup>a</sup>
3+4	9	7	2	
4+3	5	5	0	
4+4, 3+5, 5+3	7	6	1	
5+5, 5+4, 4+5	6	5	1	
Pathological staging,				
pT2N0	27	26	1	0.177 <sup>a</sup>
pT3aN0	10	7	3	
pT3bN0	7	7	0	
Any T, N+	4	3	1	
Any T, Any N, M+	1	1	0	
NEPC	1	1	0	

<sup>a</sup>Fisher's exact test. PCa, prostate cancer; CI, confidence interval; SD, standard deviation; NEPC, neuroendocrine prostate cancer.